Matinas BioPharma (MTNB) 10% Owner Sanitam Partners Sells Derivatives

What Happened
Sanitam Partners LLC, a 10% owner of Matinas BioPharma Holdings, reported dispositions of derivative securities on June 10, 2026. The filing shows two derivative disposals: 1,406 derivative shares at $0.59 each (aggregate $824) and 4,798,636 derivative shares at $0.64 each (aggregate $3,093,201). According to the filing, Sanitam distributed its holdings in the registrant’s preferred stock and warrants to its members and therefore no longer beneficially owns any securities of the company. This was a disposition (not a market purchase); distributions to members can be an internal reallocation rather than an open-market sale.

Key Details

• Transaction date: 2026-06-10; Filing date: 2026-08-13 (late Form 4 filing).
• Reported derivative disposals: 1,406 @ $0.59 = $824; 4,798,636 @ $0.64 = $3,093,201.
• Shares owned after transaction: 0 (Sanitam no longer beneficially owns any Registrant securities).
• Footnote: Sanitam distributed its preferred stock and warrants to its members (F1). The Series C convertible preferred stock is perpetual with no expiration date (F2).
• Transaction code: “J” — other acquisition/disposition involving derivative securities (not a standard open-market sale of common stock).

Context
This filing involves a 10% institutional owner redistributing derivative securities (preferred stock and warrants) to its members. Such distributions are organizational transactions and do not necessarily reflect executive trading sentiment or open-market liquidity events. The late filing delays public disclosure; Form 4s are normally due within two business days of the transaction, so the Aug 13 filing for a June 10 transaction is untimely.